In a phase I/II trial, the HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood were administered to 11 patients with relapsed or refractory CD19-positive cancers (non-Hodgkin’s lymphoma or chronic lymphocytic leukemia), of the 11 patients treated, 8 (73%) responded. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.